Oranogenesis Holdings (ORGO) PT Raised to $3.80 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Organogenesis Holding (ORGO) Tops Q3 EPS by 11c
November 12, 2024 4:33 PM ESTOrganogenesis Holding (NASDAQ: ORGO) reported Q3 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $115.2 million versus the consensus estimate of $108.83 million.
GUIDANCE:
Organogenesis Holding sees FY2024 revenue of $455-480 million, versus the consensus of $456... More
Organogenesis Holding (ORGO) Announces $130M Preferred Stock Offering
November 12, 2024 4:01 PM ESTOrganogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners (Investors) for the sale of its Series A Convertible Preferred Stock (Preferred Stock) in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses.
The Company intends to use the net proceeds from the private... More
